What data says about Tukaram Mundhe’s 100-day stint as FDA Commissioner
Data reveals a significant intensification of regulatory crackdowns on drug manufacturers and sellers by India's Food and Drug Administration (FDA) during Commissioner Tukaram Mundhe's first 100 days, with substantial increases in complaints, investigations, searches, and seizures compared to previous periods. While overall monthly regulatory actions saw a modest increase, the FDA emphasized large-scale inspections.
Why it matters
This analysis provides insight into a new commissioner's impact on a critical regulatory body, indicating a shift towards stricter enforcement in the pharmaceutical sector, which could have implications for public health, drug quality, and industry practices in India.
Regulatory crackdown on drug manufacturers and sellers by the Food and Drug Administration (FDA) has intensified drastically over the last three months, especially when compared to the last five years, data perused by The Hindu showed.
However, data also show that there has not been a huge spike in regulatory actions like cancellation and suspension of licences. The average number of regulatory actions per month has increased from approximately 258 over the five years to 293 during June-August 2026.
The number of inspections of Ayurvedic manufacturers stood at 203 for 2021-22; 279 in 2022-23; 371 in 2023-24. In the next financial year, the number of inspections rose to 427 in 12 months. But in the last quarter from June to August 2026 alone, the inspections of Ayurvedic manufacturers reached 301.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in